Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.25.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating Expenses    
Research and development expenses $ 1,588,540 $ 1,539,070
General and administrative expenses 1,258,450 1,270,528
Operating Loss (2,846,990) (2,809,598)
Other Income, net 12,585 83,217
Net Loss $ (2,834,405) $ (2,726,381)
Net Loss Per Common Share - Basic $ (0.30) $ (1.11)
Net Loss Per Common Share - Diluted $ (0.30) $ (1.11)
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic 9,526,796 2,466,523
Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted 9,526,796 2,466,523